Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 232


A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.

Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RA.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3381-8.


The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.

Fidler MJ, Argiris A, Patel JD, Johnson DH, Sandler A, Villaflor VM, Coon J 4th, Buckingham L, Kaiser K, Basu S, Bonomi P.

Clin Cancer Res. 2008 Apr 1;14(7):2088-94. doi: 10.1158/1078-0432.CCR-07-4013.


Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.

Reckamp K, Gitlitz B, Chen LC, Patel R, Milne G, Syto M, Jezior D, Zaknoen S.

Cancer. 2011 Feb 15;117(4):809-18. doi: 10.1002/cncr.25473. Epub 2010 Oct 4.


A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.

Liao Z, Komaki R, Milas L, Yuan C, Kies M, Chang JY, Jeter M, Guerrero T, Blumenschien G, Smith CM, Fossella F, Brown B, Cox JD.

Clin Cancer Res. 2005 May 1;11(9):3342-8.


Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.

Csiki I, Morrow JD, Sandler A, Shyr Y, Oates J, Williams MK, Dang T, Carbone DP, Johnson DH.

Clin Cancer Res. 2005 Sep 15;11(18):6634-40.


Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.

Chen L, He Y, Huang H, Liao H, Wei W.

Med Oncol. 2008;25(2):161-71. doi: 10.1007/s12032-007-9015-1. Epub 2008 Jan 3.


Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.

Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB, Ferrara CA, Yankelevitz DF, Subbaramaiah K, Pasmantier MW, Dannenberg AJ.

J Clin Oncol. 2003 Jul 15;21(14):2645-50.


Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.

Reguart N, Rosell R, Cardenal F, Cardona AF, Isla D, Palmero R, Moran T, Rolfo C, Pallarès MC, Insa A, Carcereny E, Majem M, De Castro J, Queralt C, Molina MA, Taron M.

Lung Cancer. 2014 May;84(2):161-7. doi: 10.1016/j.lungcan.2014.02.011. Epub 2014 Mar 2.


The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.

Gasparini G, Meo S, Comella G, Stani SC, Mariani L, Gamucci T, Avallone A, Lo Vullo S, Mansueto G, Bonginelli P, Gattuso D, Gion M.

Cancer J. 2005 May-Jun;11(3):209-16.


Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.

Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, Vansteenkiste J, Strausz J, Manikhas GM, Von Pawel J.

J Clin Oncol. 2007 Apr 20;25(12):1545-52.


A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.

Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, Morrow JD, Sandler AB, Shyr Y, Ye F, Choy H.

Clin Cancer Res. 2009 Mar 15;15(6):2158-65. doi: 10.1158/1078-0432.CCR-08-0629. Epub 2009 Mar 10.


Bexarotene and erlotinib for aerodigestive tract cancer.

Dragnev KH, Petty WJ, Shah S, Biddle A, Desai NB, Memoli V, Rigas JR, Dmitrovsky E.

J Clin Oncol. 2005 Dec 1;23(34):8757-64.


Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.

Reckamp KL, Gardner BK, Figlin RA, Elashoff D, Krysan K, Dohadwala M, Mao J, Sharma S, Inge L, Rajasekaran A, Dubinett SM.

J Thorac Oncol. 2008 Feb;3(2):117-24. doi: 10.1097/JTO.0b013e3181622bef.


Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.

Janjigian YY, Azzoli CG, Krug LM, Pereira LK, Rizvi NA, Pietanza MC, Kris MG, Ginsberg MS, Pao W, Miller VA, Riely GJ.

Clin Cancer Res. 2011 Apr 15;17(8):2521-7. doi: 10.1158/1078-0432.CCR-10-2662. Epub 2011 Jan 19.


Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer.

Krzakowski M, Bennouna J, Dansin E, Kowalski D, Hiret S, Penel N, Favrel S, Tourani JM.

Cancer Chemother Pharmacol. 2014 Feb;73(2):231-6. doi: 10.1007/s00280-013-2342-3. Epub 2013 Nov 13.


Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.

Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM.

J Clin Oncol. 2011 Nov 10;29(32):4320-6. doi: 10.1200/JCO.2011.35.5214. Epub 2011 Oct 11.


Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.

Agarwala A, Fisher W, Bruetman D, McClean J, Taber D, Titzer M, Juliar B, Yu M, Breen T, Einhorn LH, Hanna N.

J Thorac Oncol. 2008 Apr;3(4):374-9. doi: 10.1097/JTO.0b013e3181693869.


[Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].

Fan Y, Huang ZY, Yu HF, Luo LH.

Zhonghua Zhong Liu Za Zhi. 2010 Nov;32(11):859-63. Chinese.


Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial.

Nugent FW, Mertens WC, Graziano S, Levitan N, Collea R, Gajra A, Marshall J, McCann J.

Lung Cancer. 2005 May;48(2):267-73.


Supplemental Content

Support Center